NCT00459862 · STUDY IN CONTEXT

Pazopanib in Treating Patients With Malignant Pleural Mesothelioma

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

The proportion of patients who are progression-free at 6 months is calculated by dividing the number of evaluable participants who are progression-free at 6 months based on the Response Evaluation Criteria for Solid Tumors (RECIST) by the total number of evaluable participants.

All 34 participants were analyzed for this endpoint.

→

secondary · POSTED

Overall Survival

All 34 participants were evaluable for this endpoint.

→

secondary · POSTED

Progression-free Survival Assessed by RECIST

All 34 participants were analyzed for this endpoint.

→

secondary · POSTED

The number of participants with a reported Grade 3, Grade 4, and Grade 5 toxicity, regardless of attribution, will be tabulated.

All 34 participants were evaluable for adverse events.

→

secondary · POSTED

Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline LD.

All 34 participants were evaluable for this endpoint.

→

secondary · POSTED

To evaluate the confirmed response rate of pazopanib in patients with MPM based on the RECIST criteria for MPM. Responses are confirmed by repeat assessments that are be performed no less than 4 weeks after the criteria for response are first met. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.

All 34 participants were evaluable for this endpoint.

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-malignant-mesothelioma
nct id: NCT00459862
trial label: Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
applicability: narrower
applicability note: Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 6
harms Count: 1
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00459862
outcome key
om-0000
source section id
NCT00459862-om-0000
source outcome index
0
endpoint
Proportion of Evaluable Participants Who Are Progression-free at 6 Months Based on the Response Evaluation Criteria for Solid Tumors (RECIST)
endpoint definition
The proportion of patients who are progression-free at 6 months is calculated by dividing the number of evaluable participants who are progression-free at 6 months based on the Response Evaluation Criteria for Solid Tumors (RECIST) by the total number of evaluable participants.
time origin
6 months
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
All 34 participants were analyzed for this endpoint.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00459862
outcome key
om-0001
source section id
NCT00459862-om-0001
source outcome index
1
endpoint
Overall Survival
endpoint definition
Overall Survival
time origin
From study enrollment to time of death from any cause or censored at last follow-up, up to 3 years
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
All 34 participants were evaluable for this endpoint.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00459862
outcome key
om-0002
source section id
NCT00459862-om-0002
source outcome index
2
endpoint
Progression-free Survival Assessed by RECIST
endpoint definition
Progression-free Survival Assessed by RECIST
time origin
From study enrollment to the first date of disease progression or death as a result of any cause, whichever occurs first, up to 3 years
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
All 34 participants were analyzed for this endpoint.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00459862
outcome key
om-0003
source section id
NCT00459862-om-0003
source outcome index
3
endpoint
Determine the Clinical Toxicities of This Drug in This Participant Population.
endpoint definition
The number of participants with a reported Grade 3, Grade 4, and Grade 5 toxicity, regardless of attribution, will be tabulated.
time origin
Participants will be evaluated every cycle during treatment
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
All 34 participants were evaluable for adverse events.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00459862
outcome key
om-0004
source section id
NCT00459862-om-0004
source outcome index
4
endpoint
Overall Best Response of Target Lesions to Pazopanib in Patients With MPM Based on the RECIST.
endpoint definition
Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline LD.
time origin
From study enrollment to the first date of disease progression
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
All 34 participants were evaluable for this endpoint.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00459862
outcome key
om-0005
source section id
NCT00459862-om-0005
source outcome index
5
endpoint
Overall Response Rate
endpoint definition
To evaluate the confirmed response rate of pazopanib in patients with MPM based on the RECIST criteria for MPM. Responses are confirmed by repeat assessments that are be performed no less than 4 weeks after the criteria for response are first met. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.
time origin
Participants will be evaluated every cycle during treatment, up to 2 years
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
All 34 participants were evaluable for this endpoint.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00459862
outcome key
om-0000
arm key
OG000
arm label
Arm I
regimen
Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
analyzed count
34
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00459862-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00459862
outcome key
om-0001
arm key
OG000
arm label
Arm I
regimen
Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
analyzed count
34
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00459862-om-0001#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00459862
outcome key
om-0002
arm key
OG000
arm label
Arm I
regimen
Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
analyzed count
34
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00459862-om-0002#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00459862
outcome key
om-0003
arm key
OG000
arm label
Arm I
regimen
Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
analyzed count
34
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00459862-om-0003#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00459862
outcome key
om-0004
arm key
OG000
arm label
Arm I
regimen
Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
analyzed count
34
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00459862-om-0004#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00459862
outcome key
om-0005
arm key
OG000
arm label
Arm I
regimen
Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
analyzed count
34
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00459862-om-0005#groups/OG000

harms

release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00459862
harm key
EG000
source section id
NCT00459862-ae
event group key
EG000
event group label
Arm I
serious affected
13
serious at risk
34
other affected
34
other at risk
34
frequency threshold
0
collection period
Source null
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice